A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Bempedoic Acid and Ezetimibe (Nexlizet)

Adenosine Triphosphate-Citrate Lyase Inhibitor class · 0 generic manufacturers · 0 ANDAs filed at FDA.

First FDA approval2020-03-09
Generic availableNo (brand-only)
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one
Lowest NADAC
$13.84/unit
1 NDCs benchmarked, lowest of all strengths.
Average NADAC
$13.84
Across all dosage forms in distribution.
Highest NADAC
$13.84
Range is tight.
Plans with PA
144 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema11 entries indexed · 4 visible
What is Bempedoic Acid and Ezetimibe used for?

Bempedoic Acid and Ezetimibe is a Adenosine Triphosphate-Citrate Lyase Inhibitor medication tracked in Medicare Part D.

Is there a generic for Bempedoic Acid and Ezetimibe?

No. Bempedoic Acid and Ezetimibe is brand-only with no generic equivalents currently in market.

How much does my plan pay for Bempedoic Acid and Ezetimibe?

Across 329 Part D plans, Bempedoic Acid and Ezetimibe averages $13.84/unit (NADAC). Lowest available: $13.84/unit. Highest in distribution: $13.84/unit.

Is Bempedoic Acid and Ezetimibe on the FDA shortage list?

No. Bempedoic Acid and Ezetimibe is not currently on the FDA Drug Shortage Database.

7 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Adenosine Triphosphate-Citrate Lyase Inhibitor1 alternative in D1
01
Bempedoic Acid
Brand: Nexletol
$13.80Lowest NADAC
0Generic mfrs
$118.1MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (1 approvals on file) · NADAC unit costs: CMS NADAC weekly file (1 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.